Search results
Showing 61 to 75 of 110 results for dexamethasone
Drug-eluting stents for the treatment of coronary artery disease (TA152)
Evidence-based recommendations on using drug-eluting stents in adults.
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
Discontinued Reference number: GID-TAG511
Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.
Dexamethasone and hydrocortisone are both corticosteroids; they have a role in treating COVID-19 in certain people.
Awaiting development Reference number: GID-TA12030 Expected publication date: TBC
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)
Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for treating multiple myeloma in adults.
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
Awaiting development Reference number: GID-TA12466 Expected publication date: TBC
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]
Discontinued Reference number: GID-TA10254
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
Discontinued Reference number: GID-TA10353
Discontinued Reference number: GID-TA10171
Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.
Evidence-based recommendations on using coronary artery stents in adults.
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.